Fig. 1. Evaluation of BKM120 encapsulation in HE12–SNAs. (a) Reversed phase HPLC analysis of HE12–SNAs (black), ssDNA control (red) and buffer control (blue) following drug purification. Detection at absorbance wavelength 260 nm (left panel) and 320 nm (right panel). The presence of a BKM120 peak solely in HE12–SNA samples suggests drug encapsulation. (b) UV-Vis measurements of BKM120-incubated HE12–SNAs (black), ssDNA control (red) and buffer control (blue) following purification. Drug encapsulation and loading capacity were determined by RP-HPLC and separately confirmed by UV-Vis measurements. The presence of a diagnostic drug peak at 320 nm in the HE12–DNA nanoparticle sample indicates drug encapsulation. (c) In vitro release of BKM120 loaded into HE12–SNAs studied by a dialysis method over 1 day at room temperature in 1× TAMg, measured in triplicate. Error bars represent the standard deviation of measurements.
